Senti Biosciences is trading 5.8% down at $0.97 today amid broader biotech sector weakness and risk-off sentiment, with no new company-specific developments reported.
- The decline follows recent strength driven by optimism surrounding the company's gene-circuit cell therapy pipeline and favorable analyst price targets.
- No fresh catalysts or filings were reported for July 13; recent regulatory activity focused on April 2026 convertible notes financing and a prior holding-company reorganization.
- The stock's movement appears to be tracking the general downward trend in the biotechnology sector rather than reacting to internal news.